Comparison the effect of Metformin and Rosiglitazone, alone and in combination, to treat polycystic ovary syndrome.

Investigation and comparison of the effect of metformin and rosiglitazone alone and in combination on ovarian and endometrium among polycystic ovarian syndrome patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201605257513N12

Enrollment

Registered

2016-07-22

Start date

2013-03-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovarian syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: Metformin intervention group: Patients well be followed without any drug for the first 6 weeks. Then they will receive metformin alone for 12 weeks. After that they will receive the co

Treatment - Drugs

Metformin intervention group: Patients well be followed without any drug for the first 6 weeks. Then they will receive metformin alone for 12 weeks. After that they will receive the combination of me

Rosiglitazone intervention group: Patients well be followed without any drug for the first 6 weeks. Then they will receive rosiglitazone alone for 12 weeks. After that they will receive the combinati

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: females between 18-40 years old; euthyroid; non smoker; normal physical condition; not consumption of drugs that change sexual hormones metabolism for at least 1 month before trial; not using contraceptive pills for at least 3 months before the trial. Exclusion criteria: classic 21_hydroxilase deficiency; hyperprolactinemia; androgen producing tumor; pregnancy; impaired liver tests or kidney function disorder; type 2 Diabetes; anemia; thrombocytopenia; explicit hypertension.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Ovarian size. Timepoint: At the beginning of the study, after one-drug usage period, after the period of treatment with combination of two drugs. Method of measurement: Trans vaginal sonography.;Endometrium density. Timepoint: At the beginning of the study, after one-drug usage period, after the period of treatment with combination of two drugs. Method of measurement: Trans vaginal sonography.	—

Secondary

Measure	Time frame
Blood sugar. Timepoint: At the beginning of the study, after one-drug usage period, after the period of treatment with combination of two drugs. Method of measurement: Laboratory tests.;Hirsutism. Timepoint: At the beginning of the study, after one-drug usage period, after the period of treatment with combination of two drugs. Method of measurement: Ferriman criteria.;BMI. Timepoint: At the beginning of the study, after one-drug usage period, after the period of treatment with combination of two drugs. Method of measurement: Division of weight to squared hieght.	—

Measure

Time frame

Blood sugar. Timepoint: At the beginning of the study, after one-drug usage period, after the period of treatment with combination of two drugs. Method of measurement: Laboratory tests.;Hirsutism. Timepoint: At the beginning of the study, after one-drug usage period, after the period of treatment with combination of two drugs. Method of measurement: Ferriman criteria.;BMI. Timepoint: At the beginning of the study, after one-drug usage period, after the period of treatment with combination of two drugs. Method of measurement: Division of weight to squared hieght.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Ferdos Mebrabian

Isfahan University of Medical Sciences

Maryam.roozbahan.77@gmail.com+98 31 3669 2277

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026